Cargando…
Gene expression profiling impacts treatment decision making in newly diagnosed multiple myeloma patients in the prospective PROMMIS trial
Multiple myeloma (MM) is a heterogeneous hematologic malignancy associated with several risk factors including genetic aberrations which impact disease response and survival. Thorough risk classification is essential to select the best clinical strategy to optimize outcomes. The SKY92 molecular sign...
Autores principales: | , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9175784/ https://www.ncbi.nlm.nih.gov/pubmed/35844693 http://dx.doi.org/10.1002/jha2.209 |
_version_ | 1784722522222100480 |
---|---|
author | Biran, Noa Dhakal, Binod Lentzsch, Suzanne Siegel, David Usmani, Saad Z. Rossi, Adriana Rosenbaum, Cara Bhutani, Divaya Vesole, David H. Rodriguez, Cesar Nooka, Ajay K. van Rhee, Frits Stork‐Sloots, Lisette de Snoo, Femke Bhattacharyya, Pritish K. Dash, Durga Prasad Zümrütçü, Sena van Vliet, Martin H. Hari, Parameswaran Niesvizky, Ruben |
author_facet | Biran, Noa Dhakal, Binod Lentzsch, Suzanne Siegel, David Usmani, Saad Z. Rossi, Adriana Rosenbaum, Cara Bhutani, Divaya Vesole, David H. Rodriguez, Cesar Nooka, Ajay K. van Rhee, Frits Stork‐Sloots, Lisette de Snoo, Femke Bhattacharyya, Pritish K. Dash, Durga Prasad Zümrütçü, Sena van Vliet, Martin H. Hari, Parameswaran Niesvizky, Ruben |
author_sort | Biran, Noa |
collection | PubMed |
description | Multiple myeloma (MM) is a heterogeneous hematologic malignancy associated with several risk factors including genetic aberrations which impact disease response and survival. Thorough risk classification is essential to select the best clinical strategy to optimize outcomes. The SKY92 molecular signature classifies patients as standard‐ or high‐risk for progression. The PRospective Observational Multiple Myeloma Impact Study (PROMMIS; NCT02911571) measures impact of SKY92 on risk classification and treatment plan. Newly diagnosed MM patients had bone marrow aspirates analyzed for SKY92. Physicians completed a questionnaire for each patient capturing risk classification, hypothetical treatment plan, and physician confidence in the treatment plan, before and after unblinding SKY92. One hundred forty seven MM patients were enrolled. Before unblinding SKY92, physicians regarded 74 (50%) patients as clinical standard‐risk. After unblinding SKY92, 16 patients were re‐assigned as high‐risk by the physician, and for 15 of them treatment strategy was impacted, resulting in an escalated treatment plan. For the 73 (50%) clinical high‐risk patients, SKY92 indicated 46 patients to be standard‐risk; for 31 of these patients the treatment strategy was impacted consistent with a de‐escalation of risk. Overall, SKY92 impacted treatment decisions in 37% of patients (p < 0.001). For clinical decision‐making, physicians incorporated SKY92, and the final assigned clinical risk was in line with SKY92 for 89% of patients. Furthermore, SKY92 significantly increased the confidence of the physicians’ treatment decisions (p < 0.001). This study shows potential added value of SKY92 in MM for treatment decision making. |
format | Online Article Text |
id | pubmed-9175784 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-91757842022-07-14 Gene expression profiling impacts treatment decision making in newly diagnosed multiple myeloma patients in the prospective PROMMIS trial Biran, Noa Dhakal, Binod Lentzsch, Suzanne Siegel, David Usmani, Saad Z. Rossi, Adriana Rosenbaum, Cara Bhutani, Divaya Vesole, David H. Rodriguez, Cesar Nooka, Ajay K. van Rhee, Frits Stork‐Sloots, Lisette de Snoo, Femke Bhattacharyya, Pritish K. Dash, Durga Prasad Zümrütçü, Sena van Vliet, Martin H. Hari, Parameswaran Niesvizky, Ruben EJHaem Haematologic Malignancy ‐ Plasma Cell Multiple myeloma (MM) is a heterogeneous hematologic malignancy associated with several risk factors including genetic aberrations which impact disease response and survival. Thorough risk classification is essential to select the best clinical strategy to optimize outcomes. The SKY92 molecular signature classifies patients as standard‐ or high‐risk for progression. The PRospective Observational Multiple Myeloma Impact Study (PROMMIS; NCT02911571) measures impact of SKY92 on risk classification and treatment plan. Newly diagnosed MM patients had bone marrow aspirates analyzed for SKY92. Physicians completed a questionnaire for each patient capturing risk classification, hypothetical treatment plan, and physician confidence in the treatment plan, before and after unblinding SKY92. One hundred forty seven MM patients were enrolled. Before unblinding SKY92, physicians regarded 74 (50%) patients as clinical standard‐risk. After unblinding SKY92, 16 patients were re‐assigned as high‐risk by the physician, and for 15 of them treatment strategy was impacted, resulting in an escalated treatment plan. For the 73 (50%) clinical high‐risk patients, SKY92 indicated 46 patients to be standard‐risk; for 31 of these patients the treatment strategy was impacted consistent with a de‐escalation of risk. Overall, SKY92 impacted treatment decisions in 37% of patients (p < 0.001). For clinical decision‐making, physicians incorporated SKY92, and the final assigned clinical risk was in line with SKY92 for 89% of patients. Furthermore, SKY92 significantly increased the confidence of the physicians’ treatment decisions (p < 0.001). This study shows potential added value of SKY92 in MM for treatment decision making. John Wiley and Sons Inc. 2021-05-11 /pmc/articles/PMC9175784/ /pubmed/35844693 http://dx.doi.org/10.1002/jha2.209 Text en © 2021 The Authors. eJHaem published by British Society for Haematology and John Wiley & Sons Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Haematologic Malignancy ‐ Plasma Cell Biran, Noa Dhakal, Binod Lentzsch, Suzanne Siegel, David Usmani, Saad Z. Rossi, Adriana Rosenbaum, Cara Bhutani, Divaya Vesole, David H. Rodriguez, Cesar Nooka, Ajay K. van Rhee, Frits Stork‐Sloots, Lisette de Snoo, Femke Bhattacharyya, Pritish K. Dash, Durga Prasad Zümrütçü, Sena van Vliet, Martin H. Hari, Parameswaran Niesvizky, Ruben Gene expression profiling impacts treatment decision making in newly diagnosed multiple myeloma patients in the prospective PROMMIS trial |
title | Gene expression profiling impacts treatment decision making in newly diagnosed multiple myeloma patients in the prospective PROMMIS trial |
title_full | Gene expression profiling impacts treatment decision making in newly diagnosed multiple myeloma patients in the prospective PROMMIS trial |
title_fullStr | Gene expression profiling impacts treatment decision making in newly diagnosed multiple myeloma patients in the prospective PROMMIS trial |
title_full_unstemmed | Gene expression profiling impacts treatment decision making in newly diagnosed multiple myeloma patients in the prospective PROMMIS trial |
title_short | Gene expression profiling impacts treatment decision making in newly diagnosed multiple myeloma patients in the prospective PROMMIS trial |
title_sort | gene expression profiling impacts treatment decision making in newly diagnosed multiple myeloma patients in the prospective prommis trial |
topic | Haematologic Malignancy ‐ Plasma Cell |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9175784/ https://www.ncbi.nlm.nih.gov/pubmed/35844693 http://dx.doi.org/10.1002/jha2.209 |
work_keys_str_mv | AT birannoa geneexpressionprofilingimpactstreatmentdecisionmakinginnewlydiagnosedmultiplemyelomapatientsintheprospectiveprommistrial AT dhakalbinod geneexpressionprofilingimpactstreatmentdecisionmakinginnewlydiagnosedmultiplemyelomapatientsintheprospectiveprommistrial AT lentzschsuzanne geneexpressionprofilingimpactstreatmentdecisionmakinginnewlydiagnosedmultiplemyelomapatientsintheprospectiveprommistrial AT siegeldavid geneexpressionprofilingimpactstreatmentdecisionmakinginnewlydiagnosedmultiplemyelomapatientsintheprospectiveprommistrial AT usmanisaadz geneexpressionprofilingimpactstreatmentdecisionmakinginnewlydiagnosedmultiplemyelomapatientsintheprospectiveprommistrial AT rossiadriana geneexpressionprofilingimpactstreatmentdecisionmakinginnewlydiagnosedmultiplemyelomapatientsintheprospectiveprommistrial AT rosenbaumcara geneexpressionprofilingimpactstreatmentdecisionmakinginnewlydiagnosedmultiplemyelomapatientsintheprospectiveprommistrial AT bhutanidivaya geneexpressionprofilingimpactstreatmentdecisionmakinginnewlydiagnosedmultiplemyelomapatientsintheprospectiveprommistrial AT vesoledavidh geneexpressionprofilingimpactstreatmentdecisionmakinginnewlydiagnosedmultiplemyelomapatientsintheprospectiveprommistrial AT rodriguezcesar geneexpressionprofilingimpactstreatmentdecisionmakinginnewlydiagnosedmultiplemyelomapatientsintheprospectiveprommistrial AT nookaajayk geneexpressionprofilingimpactstreatmentdecisionmakinginnewlydiagnosedmultiplemyelomapatientsintheprospectiveprommistrial AT vanrheefrits geneexpressionprofilingimpactstreatmentdecisionmakinginnewlydiagnosedmultiplemyelomapatientsintheprospectiveprommistrial AT storkslootslisette geneexpressionprofilingimpactstreatmentdecisionmakinginnewlydiagnosedmultiplemyelomapatientsintheprospectiveprommistrial AT desnoofemke geneexpressionprofilingimpactstreatmentdecisionmakinginnewlydiagnosedmultiplemyelomapatientsintheprospectiveprommistrial AT bhattacharyyapritishk geneexpressionprofilingimpactstreatmentdecisionmakinginnewlydiagnosedmultiplemyelomapatientsintheprospectiveprommistrial AT dashdurgaprasad geneexpressionprofilingimpactstreatmentdecisionmakinginnewlydiagnosedmultiplemyelomapatientsintheprospectiveprommistrial AT zumrutcusena geneexpressionprofilingimpactstreatmentdecisionmakinginnewlydiagnosedmultiplemyelomapatientsintheprospectiveprommistrial AT vanvlietmartinh geneexpressionprofilingimpactstreatmentdecisionmakinginnewlydiagnosedmultiplemyelomapatientsintheprospectiveprommistrial AT hariparameswaran geneexpressionprofilingimpactstreatmentdecisionmakinginnewlydiagnosedmultiplemyelomapatientsintheprospectiveprommistrial AT niesvizkyruben geneexpressionprofilingimpactstreatmentdecisionmakinginnewlydiagnosedmultiplemyelomapatientsintheprospectiveprommistrial |